AlterDiag will take full responsibility for the industrialization, regulatory restrictions, and commercialization of the tests.

The firm reported that its full-year 2024 revenues were up slightly as a rise in the diagnostics business was mostly offset by a decline in life sciences business.

The firm reported that its full-year 2024 revenues were up slightly as a rise in the diagnostics business was mostly offset by a decline in life sciences business.

The small Baltimore-based lab is preparing for the possibility of additional appeals as years of litigation wind down.

NEW YORK – Danaher executives said Wednesday that the firm expects the effects from the volume-based procurement program in China and anticipated lower respiratory testing volumes will have an impact ...

Quest said that while it will continue to look at acquisition opportunities, it plans to focus on integrating and driving productivity of recently purchased assets.